A multi-omic approach to analyze (HR+ve) clinical cohort through; Genomics, Transcriptomics, Proteomics and Radiomics would help to identify groups of patients who can be managed with immune-therapy.
At diagnosis 84% of breast cancer patients have HR+ve tumours indicating positivity for estrogen and/or progesterone receptor (ER, PR), where estrogen and progesterone are key drivers of carcinogenesis.
Recently the contribution of the immune microenvironment and predicting patient response using either gene expression signatures or through quantitation of tumour-infiltrating lymphocytes (TIL) has been examined. Many of these studies have focused on the triple negative and HER2 list of text fields, add as many as you like Antoine (Version 3: 2020-12-08) positive subgroups as they show extensive immune infiltration and immune scores were found to be highly predictive of survival and response to chemotherapy.
At present, responses to immune checkpoint inhibitor monotherapy have been marginal in HR+ve breast cancer. However, given the prevalence of HR+ve/HER2-ve breast cancer, identifying even a small subset of immunologically “hot” HR+ve/HER2- tumors could be clinically significant and allow identification of patients likely to benefit from immunotherapy